| 1 |
NCT03618511 |
Recruiting |
Interventions to Improve HIV Antiretroviral Therapy Adherence |
- Human Immunodeficiency Virus (HIV) Infection
|
- Behavioral: Financial Incentive
- Behavioral: Reminders
- Behavioral: Financial Incentive and Reminders
|
Interventional
|
Not Applicable |
- University of Michigan
- Beira Operational Research Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Medication possession ratio (MPR) at least 95%, 6 month window
- Medication possession ratio (MPR) at least 95%, 3 month window
- Medication possession ratio (MPR) at least 80%, 6 month window
- (and 3 more...)
|
1200 |
All |
18 Years and older (Adult, Older Adult) |
NCT03618511 |
HUM00133179 |
|
August 6, 2018 |
August 2019 |
August 2019 |
August 7, 2018 |
September 14, 2018 |
|
- Munhava Health Center
Beira, Sofala, Mozambique
|
|
| 2 |
NCT03610815 |
Not yet recruiting |
Community I-STAR Mozambique: Community Implementation of SBIRT Using Technology for Alcohol Use Reduction in Mozambique |
- mSBIRT - Mobile Screening, Brief Intervention, Referral to Treatment
- SBIRT-CTS - Screening, Brief Intervention, Referral to Treatment Conventional Training and Supervision Strategy
|
- Behavioral: Screening, Brief Intervention, Referral to Treatment
|
Interventional
|
Phase 4 |
- New York State Psychiatric Institute
- Columbia University
- University of Pennsylvania
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Health Services Research
|
- Implementation - Reach
- Clinical Effectiveness - AUDIT
- Cost of Implementing New Strategies (COINS)
|
275 |
All |
18 Years and older (Adult, Older Adult) |
NCT03610815 |
7493 |
|
July 1, 2019 |
June 30, 2024 |
June 30, 2024 |
August 1, 2018 |
August 1, 2018 |
|
- MIHER: Mozambique Institute for Health Education and Research
Maputo, Mozambique
|
|
| 3 |
NCT03610750 |
Not yet recruiting |
Training Providers to Conduct PRIDES-sSA |
- Common Mental Disorders
- Severe Mental Disorder
|
- Other: psychiatric medications and evidence-based psychotherapies
|
Interventional
|
Phase 4 |
- New York State Psychiatric Institute
- Columbia University
- University of Pennsylvania
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Health Services Research
|
- Change in Reach (implementation)
- Cost
- Change in Retention (implementation)
- Change in Clinical symptoms
|
901 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03610750 |
7485 |
PRIDE-sSA |
December 1, 2018 |
December 2021 |
December 2021 |
August 1, 2018 |
August 1, 2018 |
|
- MIHER: Mozambique Institute for Health Education and Research
Maputo, Mozambique
|
|
| 4 |
NCT03425136 |
Recruiting |
Systems Analysis and Improvement Approach for Prevention of MTC HIV Transmission |
|
- Other: Systems Analysis and Improvement Approach (SAIA)
|
Interventional
|
Not Applicable |
- University of Washington
- Ministry of Health, Mozambique
- Health Alliance International
- (and 2 more...)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Maternal retention in care, evaluated using clinic registry data
- Maternal viral load assessment, evaluated using clinic registry data
- Early Infant Diagnosis for HIV, evaluated using clinic registry data
- (and 4 more...)
|
36 |
All |
15 Years and older (Child, Adult, Older Adult) |
NCT03425136 |
STUDY00000645
1R01MH113435 |
SAIA-SCALE |
February 1, 2018 |
July 2021 |
August 2021 |
February 7, 2018 |
October 11, 2018 |
|
- Manica Province
Chimoio, Manica, Mozambique
|
|
| 5 |
NCT03313128 |
Recruiting |
SaniVac Trial - Sanitation and Oral Rotavirus Vaccine Performance |
- Rotavirus Infections
- Environmental Enteric Dysfunction
- Enteric Infections
|
|
Observational
|
|
- London School of Hygiene and Tropical Medicine
- Instituto Nacional de Saúde, Mozambique
- Georgia Institute of Technology
- Centers for Disease Control and Prevention
|
Other / U.S. Fed |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Oral rotavirus vaccine seroconversion
- Enteric infection
- Environmental Enteric Dysfunction
|
200 |
Female |
16 Years and older (Child, Adult, Older Adult) |
NCT03313128 |
QA919 |
|
October 1, 2017 |
December 31, 2018 |
December 31, 2018 |
October 18, 2017 |
October 24, 2017 |
|
- Centro de Investigação em Saúde da Polana Caniço (CISPOC)
Maputo, Mozambique
|
|
| 6 |
NCT03149237 |
Recruiting |
Partners-based HIV Treatment for Couples Attending Antenatal Care |
- Human Immunodeficiency Virus
|
- Behavioral: Couples-based services
|
Interventional
|
Not Applicable |
- Vanderbilt University Medical Center
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
|
3240 |
All |
18 Years and older (Adult, Older Adult) |
NCT03149237 |
170365
R01MH113478-01 |
|
November 20, 2017 |
April 2022 |
April 2022 |
May 11, 2017 |
January 25, 2018 |
|
- Minisitry of Health Health Facility
Pebane, Zambezia, Mozambique
|
|
| 7 |
NCT03076359 |
Recruiting |
Traditional Healers as Adherence Partners for Persons Living With HIV in Rural Mozambique |
|
- Behavioral: Traditional Healer Support Program
- Drug: Standard of Care
|
Interventional
|
Not Applicable |
- Vanderbilt University Medical Center
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Retention in Care
- Viral Load
|
340 |
All |
18 Years and older (Adult, Older Adult) |
NCT03076359 |
150217
K01MH107255-01 |
PLHIV |
June 10, 2015 |
May 30, 2019 |
May 30, 2019 |
March 10, 2017 |
March 27, 2018 |
|
- Namacurra Sede Health Facility
Namacurra, Zambezia, Mozambique
|
|
| 8 |
NCT02698748 |
Completed |
Evaluating the Role of Chloroquine for Malaria Elimination |
|
- Drug: Chloroquine
- Drug: Placebo
|
Interventional
|
Phase 2
Phase 3 |
- Centro de Investigacao em Saude de Manhica
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Prevention
|
- Adequate parasitologic response (APR) to therapy
- Early parasitologic failure
- Late parasitologic failure
- (and 4 more...)
|
75 |
Male |
18 Years and older (Adult, Older Adult) |
NCT02698748 |
CNBS (173/CNBS/13) |
Cloroquina |
January 2015 |
April 2015 |
June 2015 |
March 4, 2016 |
February 7, 2018 |
|
- Centro de Investigaçao em Saude de Manhiça
Manhiça, Maputo, Mozambique
|
|
| 9 |
NCT02694874 |
Recruiting |
Rosiglitazone Adjunctive Therapy for Severe Malaria in Children |
|
- Drug: Rosiglitazone
- Drug: Placebo
|
Interventional
|
Not Applicable |
- Centro de Investigacao em Saude de Manhica
- University Health Network, Toronto
- Barcelona Institute for Global Health
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in serum Ang-2 levels in the first 96 hours of hospital admission.
- Time to clinical recovery
- Time to parasitological recovery
- (and 8 more...)
|
210 |
All |
12 Months to 12 Years (Child) |
NCT02694874 |
ROSI_v03_22072015 |
ROSI |
February 2016 |
August 2019 |
December 2019 |
March 1, 2016 |
February 7, 2018 |
|
- Centro de Investigação em Saude da Manhiça
Manhiça, Maputo, Mozambique
|
|
| 10 |
NCT02371265 |
Completed |
Early ART Initiation Among HIV-positive Pregnant Women in Central Mozambique |
|
- Other: Adherence and retention package
|
Interventional
|
Not Applicable |
- University of Washington
- Health Alliance International
- Beira Operations Research Center, Mozambique Ministry of Health
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Retention at 30 days
- Adherence at 90 days
|
761 |
Female |
14 Years to 50 Years (Child, Adult) |
NCT02371265 |
1R01HD074557-01 |
|
April 2012 |
August 2015 |
August 2015 |
February 25, 2015 |
May 13, 2016 |
|
- Beira Operations Research Center
Beira, Sofala, Mozambique
|
|
| 11 |
NCT02362932 |
Recruiting |
The Effect of an Urban Sanitation Intervention on Child Health |
|
|
Interventional
|
Not Applicable |
- London School of Hygiene and Tropical Medicine
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Combined prevalence of bacterial and protozoan enteric infections
- Combined helminth re-infection at 1 year following baseline de-worming
- Period prevalence (7-day recall) of gastrointestinal illness
- Height-for-age z-score
|
2000 |
All |
up to 48 Months (Child) |
NCT02362932 |
8345 |
MapSan |
February 2015 |
September 2018 |
September 2018 |
February 13, 2015 |
August 23, 2018 |
|
- Health Research for Development
Maputo, Mozambique
|
|
| 12 |
NCT01910493 |
Completed |
Evaluation of the Impact of Mobile Phone Messages on ART and PMTCT Adherence in Mozambique |
|
- Behavioral: SMS reminders
|
Interventional
|
Not Applicable |
- Absolute Return for Kids
- Vodacom
- United States Agency for International Development (USAID)
- Department for International Development, United Kingdom
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Retention in ART care
- Retention in PMTCT care
|
1352 |
All |
18 Years and older (Adult, Older Adult) |
NCT01910493 |
SMSaude01 |
SMSaude |
November 2011 |
May 2013 |
June 2013 |
July 29, 2013 |
July 29, 2013 |
|
- 6 Health Facilities
Matola, Xinavane, Machava and Namaacha, Maputo, Mozambique
|
|
| 13 |
NCT01903057 |
Withdrawn |
Safety Study of Combined Azithromycin, Ivermectin and Albendazole for Trachoma and Lymphatic Filariasis |
- Trachoma
- Lymphatic Filariasis
|
- Drug: azithromycin
- Drug: ivermectin
- Drug: albendazole
- Drug: placebo
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
|
- The overall rate of adverse events and serious adverse events in each group
- The types of adverse events and serious adverse events of triple combination therapy with azithromycin, ivermectin and albendazole, to standard sequential therapy.
- The incidences of adverse events and serious adverse events of triple combination therapy with azithromycin, ivermectin and albendazole, to standard sequential therapy.
- (and 3 more...)
|
0 |
All |
5 Years to 65 Years (Child, Adult, Older Adult) |
NCT01903057 |
IRB00065751
ITI2012-001 |
AZIVAL2 |
February 2014 |
March 2014 |
July 2014 |
July 19, 2013 |
May 22, 2014 |
|
- National Institute of Health, Ministry of Health
Maputo, Mozambique
|
|
| 14 |
NCT01688310 |
Completed
Has Results |
A Randomized Controlled Trial of Open Surgical vs. Minimally-invasive Voluntary Adult Male Circumcision |
|
- Procedure: Gomco Clamp with Tissue Adhesive
- Procedure: Open surgical circumcision
|
Interventional
|
Not Applicable |
- Universidade Católica de Moçambique
- University of Pittsburgh
- Catholic University of Mozambique
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Intraoperative Duration
- Difficulty in Learning and Performing Technique
- Time Required for Healing
- (and 4 more...)
|
200 |
Male |
18 Years and older (Adult, Older Adult) |
NCT01688310 |
PRO11080657 |
|
August 2012 |
March 2013 |
March 2013 |
September 19, 2012 |
September 10, 2013 |
September 10, 2013 |
- Centro de Saúde São Lucas, UCM
Beira, Sofala, Mozambique
|
|
| 15 |
NCT01464138 |
Completed |
Evaluation of Fosmidomycin and Clindamycin in the Treatment of Acute Uncomplicated P.Falciparum Malaria in Children |
|
- Drug: Fosmidomycin and Clindamycin co-administration
|
Interventional
|
Phase 2 |
- Jomaa Pharma GmbH
- Fundacio Clinic
- Hospital Clinic of Barcelona
|
Industry / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Day 28 cure rate >95%
- Day 7 cure rate of 100%
- Parasite Clearance Time
- Fever Clearance Time
|
52 |
All |
6 Months to 3 Years (Child) |
NCT01464138 |
JP012 |
|
September 2010 |
September 2011 |
September 2011 |
November 3, 2011 |
November 3, 2011 |
|
- Centro de Investigacao em Saude da Manhica
Maputo, Mozambique
|
|
| 16 |
NCT01407497 |
Completed |
Safety and Immunogenicity Study of a DNA Priming and MVA Boosting Strategy of HIV Vaccine |
|
- Biological: DNA HIVIS and MVA-CMDR
- Biological: Saline solution
|
Interventional
|
Phase 1 |
- Instituto Nacional de Saúde, Mozambique
- Swedish Institute for Communicable Disease Control, Sweden
- European and Developing Countries Clinical Trials Partnership (EDCTP)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Adverse events (local and system reactogenicity)
- Immunogenicity
|
25 |
All |
18 Years to 26 Years (Adult) |
NCT01407497 |
TAMOVAC-01-MZ |
|
August 2011 |
March 2013 |
August 2013 |
August 2, 2011 |
December 4, 2013 |
|
- Centro de Investigação e Treino em Saúde de Polana Caniço
Maputo, Mozambique
|
|
| 17 |
NCT00488579 |
Completed |
Routine Iron Prophylaxis During Pregnancy |
|
- Drug: Two policies of iron prophylaxis
|
Interventional
|
Phase 4 |
- National Istitute For Health and Welfare, Finland
- Academy of Finland
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Preterm delivery
- Low birth weight
- perinatal mortality, complications during pregnancy and birth
|
4326 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00488579 |
PROFEG |
PROFEG |
May 2007 |
December 2007 |
May 2016 |
June 20, 2007 |
November 30, 2017 |
|
- Universidade Eduardo Mondlande, Faculty of Medicine, Department of Community Health
Maputo, Mozambique
|
|
| 18 |
NCT00380146 |
Completed |
Pharmacokinetics, Efficacy, Gametocyte Carriage, Birth Outcomes Following Sulfadoxine-pyrimethamine Intermittent Presumptive Treatment in Pregnant Women |
|
- Drug: sulfadoxine-pyrimethamine
|
Interventional
|
Not Applicable |
- Professor Karen I Barnes
- Global Fund
- Medical Research Council, South Africa
- University of Cape Town
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Pharmacokinetic parameters by measurement of whole blood levels of sulfadoxine and pyrimethamine and plasma levels of artesunate to determine Cmax, Tmax, AUC, half life, volume of distribution and clearance
- Correlation of treatment outcome and gametocyte carriage with pharmacokinetic parameters and pregnancy status
- Correlation of frequency of DHFR mutations at codons 436, 437, 540 and 581 in maternal and placental samples with treatment outcomes
- (and 3 more...)
|
31 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00380146 |
SEACAT2.2 |
|
September 2006 |
February 2008 |
March 2008 |
September 25, 2006 |
October 26, 2016 |
|
- Ndlavela Health Centre
Ndlavela, Maputo, Mozambique
|
|
| 19 |
NCT00331708 |
Terminated |
Artesunate Plus Sulfadoxine-pyrimethamine Pharmacokinetics, Efficacy, Gametocytes Carriage and Birth Outcomes in Pregnant Women With Malaria |
|
- Drug: Artesunate plus sulfadoxine-pyrimethamine
|
Interventional
|
Not Applicable |
- Professor Karen I Barnes
- Global Fund
- Medical Research Council, South Africa
- University of Cape Town
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pharmacokinetic parameters by measurement of whole blood levels of sulfadoxine and pyrimethamine and plasma levels of artesunate and its active metabolite dihydroartemisinin to determine Cmax, Tmax, AUC, half life, volume of distribution and clearance
- Correlation of treatment outcome with pharmacokinetic parameters and pregnancy status.
- Association of gametocyte carriage with pregnancy status
- (and 4 more...)
|
3 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00331708 |
SEACAT2.1 |
|
April 2006 |
July 2007 |
July 2007 |
May 31, 2006 |
October 26, 2016 |
|
- Ndlavela Health Centre
Ndlavela, Maputo, Mozambique
|
|
| 20 |
NCT00323622 |
Completed
Has Results |
Long-Term Follow-up of Children for a 2-Year Period to Confirm the Safety and Immunogenicity of GSK 257049 Vaccine |
|
- Biological: GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049
- Biological: Engerix™-B
- Biological: Hiberix®
- (and 3 more...)
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Number of Subjects With Serious Adverse Events (SAEs)
- Anti-circumsporozoite Protein (CS) Antibody Concentrations.
- Anti-hepatitis B (HBs) Antibody Concentrations.
- (and 7 more...)
|
1737 |
All |
33 Months to 69 Months (Child) |
NCT00323622 |
104297 |
|
April 2005 |
May 2007 |
May 2007 |
May 9, 2006 |
December 9, 2016 |
March 27, 2014 |
- GSK Investigational Site
Maputo, Mozambique
|
|
| 21 |
NCT00272220 |
Completed |
Longitudinal Study of HAART, Social Networks, & Adherence |
- Acquired Immunodeficiency Syndrome
|
- Behavioral: modified directly observed therapy (mDOT)
|
Interventional
|
Not Applicable |
- University of Washington
- Mozambique Ministry of Health
- United States President's Emergency Plan for AIDS Relief
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Self-report - 7 & 30 day recall
- Change in CD4 count
|
350 |
All |
18 Years and older (Adult, Older Adult) |
NCT00272220 |
03-9137-G 01
TAP:HIV-AIDS/MS-DPC/GACOPI/04 |
|
October 2004 |
|
June 2006 |
January 4, 2006 |
November 7, 2007 |
|
- Beira Day Hosptial - Central Hospital
Beira, Sofala, Mozambique
|
|
| 22 |
NCT00231452 |
Completed |
Age of Exposure and Immunity to Malaria in Infants |
|
- Drug: Sulfadoxine-pyrimethamine (SP) + Artesunate (AS)
|
Interventional
|
Not Applicable |
- Hospital Clinic of Barcelona
- European Commission
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
|
- (Clinical) Time to first or only episode of clinical malaria in the second year of life detected by passive case detection
- (Clinical) Time to first or only episode of malaria (using other case definitions), anaemia and other clinical endpoints.
- Oxidative stress markers
- (and 2 more...)
|
349 |
All |
up to 1 Week (Child) |
NCT00231452 |
AgeMal |
|
September 2005 |
March 2009 |
March 2009 |
October 4, 2005 |
October 28, 2011 |
|
- Centro de Investigaçao em Saude da Manhiça
Manhiça, Maputo, Mozambique
|
|
| 23 |
NCT00231322 |
Completed |
Influence of Transmission Season on Outcome of Treatment of Schistosoma Haematobium Infection in Mozambique |
|
|
Interventional
|
Not Applicable |
- DBL -Institute for Health Research and Development
- Durban University of Technology South Africa
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- cure rate
- egg reduction rate
- re-infection prevalence and intensity of infection *resolution of urinary tract pathology
- (and 2 more...)
|
520 |
All |
8 Years to 12 Years (Child) |
NCT00231322 |
30/CNSB/03/624-03-0021 |
|
March 2004 |
|
March 2006 |
October 4, 2005 |
April 20, 2007 |
|
- Matola
Maputo, Maputo Province, Mozambique
|
|
| 24 |
NCT00209794 |
Unknown † |
IPTi in Mozambican Infants for Malaria Prevention |
|
- Drug: Sulfadoxine-Pyrimethamine (Fansidar)
|
Interventional
|
Phase 1
Phase 2 |
- Hospital Clinic of Barcelona
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Prevention
|
- Incidence of first or only malaria episodes in each study cohort by 12 months of age.
- Incidence of first or only malaria episodes by group up to 12 months of age as per protocol analysis.
- Incidence of first or only malaria episodes by group up to 24 months of age.
- (and 9 more...)
|
1498 |
All |
up to 3 Months (Child) |
NCT00209794 |
TIM |
|
September 2002 |
|
December 2005 |
September 21, 2005 |
November 16, 2006 |
|
- Centro de Investigaçao em Saude da Manhiça
Manhiça, Maputo, Mozambique
|
|
| 25 |
NCT00209781 |
Unknown † |
IPTp Plus ITNs for Malaria Control in Pregnant Women |
|
- Drug: Sulfadoxine-Pyrimethamine (Fansidar)
- Device: ITNs
|
Interventional
|
Not Applicable |
- Hospital Clinic of Barcelona
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Diagnostic
|
- Evaluate whether two doses of intermittent treatment with SP delivered through antenatal clinics provides additional benefit to the protection afforded by ITNs on low birth weight
- To assess whether intermittent treatment with sulfadoxine-pyrimethamine provides any additional benefit to the protection afforded by ITNs on the:
- Maternal anaemia at and after delivery
- (and 10 more...)
|
1028 |
Female |
Child, Adult, Older Adult |
NCT00209781 |
TimNet |
|
August 2003 |
|
December 2006 |
September 21, 2005 |
March 6, 2008 |
|
- Centro de Investigaçao em Saude da Manhiça
Manhiça, Maputo, Mozambique
|
|
| 26 |
NCT00197067 |
Completed |
A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Candidate Vaccines RTS,S/AS02D (0.5 mL Dose) and RTS,S/AS02A (0.25 mL Dose) Administered IM According to a 0, 1, 2 Month Vaccination Schedule in Children Aged 3 to 5 Years Living in a Malaria-endemic Region of Mozambique. |
|
- Biological: RTS,S/AS02D and RTS,S/AS02A
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Other
|
- Occurrence of solicited and unsolicited symptoms and serious adverse events during the entire study period; to assess antibody levels for relevant immunological indicators at time points when post completion of vaccination schedule.
- To assess antibody levels for relevant immunological indicators at time points when blood sampling will be done.
|
200 |
All |
3 Years to 5 Years (Child) |
NCT00197067 |
257049/034 |
|
March 15, 2004 |
April 26, 2005 |
April 26, 2005 |
September 20, 2005 |
June 2, 2017 |
|
- GSK Investigational Site
Maputo, Mozambique
|
|
| 27 |
NCT00197041 |
Completed |
A Study to Evaluate the Safety, Immunogenicity and Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Malaria Vaccine RTS,S/AS02A, When Administered to Children Aged 1 to 4 Years Living in a Malaria-endemic Region of Mozambique. |
|
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Time to the first clinical episode of symptomatic Plasmodium falciparum malaria infection detected over the 6-month surveillance period after Dose 3 vaccination.
- Occurrence of episodes of asymptomatic and symptomatic infections of Plasmodium falciparum malaria. Occurrence of solicited symptoms, unsolicited symptoms and SAEs.
|
2022 |
All |
1 Year to 4 Years (Child) |
NCT00197041 |
257049/026 |
|
July 2003 |
April 2005 |
April 2005 |
September 20, 2005 |
September 21, 2016 |
|
- GSK Investigational Site
Maputo, Mozambique
|
|
| 28 |
NCT00197028 |
Completed
Has Results |
Examine Safety and Immune Responses of GSK 257049 Vaccine When Administered to Infants Living in a Malaria-endemic Region |
|
- Biological: RTS,S/AS02D
- Biological: TETRActHib™
- Biological: Engerix-B®
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Number of Subjects With Serious Adverse Events (SAEs).
- Concentrations of Antibodies Against Hepatitis B (Anti-HB)
- Concentrations of Anti-circumsporozoite Protein (Anti-CS) Antibodies.
- (and 10 more...)
|
214 |
All |
6 Weeks to 12 Weeks (Child) |
NCT00197028 |
103967 |
|
August 23, 2005 |
December 27, 2007 |
December 27, 2007 |
September 20, 2005 |
August 20, 2018 |
January 18, 2013 |
- GSK Investigational Site
Maputo, Mozambique
|
|
| 29 |
NCT02156882 |
Completed |
Establishment of a Clinical Trial Unit in Mavalane, Maputo, in Mozambique |
|
|
Observational
|
|
- Michael Hoelscher
- Ludwig-Maximilians - University of Munich
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Number of participants with clinical and microbiological cure at month 6 after treatment initiation
|
81 |
All |
18 Years and older (Adult, Older Adult) |
NCT02156882 |
MaTuTU-TB-01 |
MaTuTU |
June 2014 |
May 2016 |
September 2016 |
June 5, 2014 |
March 7, 2018 |
|
- Centro de Investigação e Treino em Saúde da Polana Caniço
Maputo, Mozambique - Instituto Nacional de Saúde, Eduardo Mondlane Avenue nº 1008 MISAU
Maputo, Mozambique
|
|
| 30 |
NCT00203814 |
Completed |
A Randomised Efficacy Study of Combination Antimalarials to Treat Uncomplicated Malaria |
|
- Drug: Sulfadoxine-pyrimethamine
- Drug: Artesunate plus sulfadoxine-pyrimethamine
|
Interventional
|
Not Applicable |
- University of Cape Town
- World Health Organization
- Medical Research Council, South Africa
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Therapeutic efficacy defined as:Adequate Clinical and Parasitological Response (ACPR), Early Treatment Failure (ETF), Late Treatment Failure (LTF), defined as Late Clinical Failure (LCF) and Late Parasitological Failure (LPF)
- Sensitive or parasitological failure (RI, early and late, RII, RIII)
- Parasitological failures will be classified as recrudescence or re-infection (or indeterminate) using GLURP and MSP I & II markers
- (and 7 more...)
|
280 |
All |
12 Months and older (Child, Adult, Older Adult) |
NCT00203814 |
SEACAT 01a ASSP |
|
January 2004 |
|
March 2005 |
September 20, 2005 |
November 16, 2006 |
|
- Boane Clinic
Boane, Maputo, Mozambique - Magude Clinic
Magude, Mozambique
|
|
| 31 |
NCT00203736 |
Completed |
A Randomised Efficacy Study of Combination Antimalarials to Treat Uncomplicated Malaria |
|
- Drug: Sulfadoxine-pyrimethamine
- Drug: Artesunate plus sulfadoxine-pyrimethamine
|
Interventional
|
Not Applicable |
- University of Cape Town
- World Health Organization
- Medical Research Council, South Africa
- Global Fund
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Therapeutic efficacy defined as: Adequate Clinical and Parasitological Response (ACPR), Early Treatment Failure (ETF), Late Treatment Failure (LTF), defined as Late Clinical Failure (LCF) and Late Parasitological Failure (LPF)
- Sensitive or parasitological failure (RI, early and late, RII, RIII)
- Parasitological failures will be classified as recrudescence or re-infection (or indeterminate) using GLURP and MSP I & II markers
- (and 7 more...)
|
240 |
All |
12 Months and older (Child, Adult, Older Adult) |
NCT00203736 |
SEACAT 01 Am 4 (RCT) |
|
January 2003 |
|
October 2003 |
September 20, 2005 |
November 16, 2006 |
|
- Catuane Clinic
Catuane, Matutuine, Mozambique - Namaacha Clinic
Namaacha, Mozambique
|
|
| 32 |
NCT03187067 |
Recruiting |
Pediatric Pneumonia Lung Ultrasound |
- Pneumonia
- Acute Respiratory Infection
|
|
Observational
|
|
- Save the Children
- Bill and Melinda Gates Foundation
- Barcelona Institute for Global Health
- Aga Khan University
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- LUS findings at enrollment
- Repeat LUS findings
|
240 |
All |
2 Months to 23 Months (Child) |
NCT03187067 |
PLUS |
PLUS |
July 31, 2017 |
December 2018 |
December 2018 |
June 14, 2017 |
September 6, 2018 |
|
- Centro de Investigação em Saúde de Manhiça (CISM)
Manhiça, Mozambique - Aga Khan University
Karachi, Pakistan
|
|
| 33 |
NCT03671109 |
Not yet recruiting |
Improving Maternal heAlth by Reducing Malaria in African HIV Women |
- Malaria
- HIV/AIDS
- Pregnancy Related
|
- Drug: Dihydroartemisinin-piperaquine (DHA-PPQ)
- Drug: Placebo Oral Tablet
|
Interventional
|
Phase 3 |
- Barcelona Institute for Global Health
- Medicines for Malaria Venture
- Universität Tübingen
- (and 4 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Maternal parasitaemia at delivery
- Incidence of clinical malaria
- Incidence of all-cause admissions
- (and 23 more...)
|
644 |
Female |
Child, Adult, Older Adult |
NCT03671109 |
EDCTP- RIA2016MC-1613 |
MAMAH |
February 2019 |
June 2021 |
June 2022 |
September 14, 2018 |
September 14, 2018 |
|
- Centre de Recherches Médicales de Lambaréné (CERMEL)
Lambaréné, Gabon - Centro de Investigação em Saúde de Manhiça (CISM)
Manhiça, Mozambique
|
|
| 34 |
NCT01972321 |
Completed |
ICCM of Common Childhood Diseases: Mozambique and Uganda |
- Malaria
- Pneumonia
- Diarrhoea
|
- Other: Technology supported supervision
- Behavioral: Community supported supervision
- Other: Integrated community case management
|
Interventional
|
Not Applicable |
- Malaria Consortium
- London School of Hygiene and Tropical Medicine
- University College, London
- (and 2 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Appropriate treatment of malaria, pneumonia and diarrhoea in children under five years of age
- Community health workers with medicine stock-out <1 week each quarter
|
2289 |
All |
Child, Adult, Older Adult |
NCT01972321 |
OPP1002407 |
inSCALE |
April 2013 |
June 2015 |
December 2015 |
October 30, 2013 |
January 8, 2016 |
|
- 6 Districts
Inhambane, Mozambique - 26 Sub-Counties
Hoima, Please Select, Uganda
|
|
| 35 |
NCT02910934 |
Recruiting |
Cost-effectiveness Evaluation of Vector Control Strategies in Mozambique |
|
|
Interventional
|
Not Applicable |
- PATH
- United States Agency for International Development (USAID)
- Abt Associates
- (and 3 more...)
|
Other / U.S. Fed / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Health Services Research
|
- Cost per case averted in children five years of age and under at health facility level by adding Actellic-IRS
- Entomological Indicators
- Parasite prevalence
- (and 2 more...)
|
4636 |
All |
6 Months and older (Child, Adult, Older Adult) |
NCT02910934 |
946238-1 (EOM) |
COST |
January 10, 2017 |
January 10, 2019 |
March 10, 2019 |
September 22, 2016 |
June 8, 2017 |
|
- Molly Robertson
Washington, D.C., District of Columbia, United States - Centro de Investigacoes de Manhica
Manhica, Maputo, Mozambique
|
|
| 36 |
NCT01681914 |
Completed |
Assessment of the Effectiveness of New Clinical Guidelines for Differential Diagnosis and Management of Common HIV/AIDS-related Conditions in Mozambique |
|
|
Observational
|
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- 1. What proportion of HIV-infected adult patients with common signs and symptoms can be assigned specific, potentially treatable diagnoses or syndromic classifications when evaluated in conformity with new Mozambican algorithms?
- 2. What diagnoses or syndromic classifications are assigned to patients managed per protocol (in accordance with the new algorithms)
- 3. What are the confirmed or probable diagnoses of patients who improve when managed in accordance with the new algorithms?
- (and 4 more...)
|
492 |
All |
18 Years and older (Adult, Older Adult) |
NCT01681914 |
100803
U2GPS000631-05 |
|
April 2012 |
September 2012 |
September 2012 |
September 10, 2012 |
August 13, 2013 |
|
- Inhassunge District Health Facility
Inhassunge, Mozambique - Namacurra District Health Facility
Namacurra, Mozambique - Coalane Health Facility
Quelimane, Mozambique
|
|
| 37 |
NCT00495326 |
Completed |
Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146 CARINEMO) |
- Tuberculosis
- Aids
- Hiv Infections
|
- Drug: Nevirapine based therapy
- Drug: Efavirenz based therapy
- Drug: Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z)
|
Interventional
|
Phase 2
Phase 3 |
- French National Agency for Research on AIDS and Viral Hepatitis
- Medecins Sans Frontieres, Netherlands
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Viral load measure (Virological failure will be defined after 2 consecutive measures as : More than 1 log10 increase in plasma HIV-1 RNA concentration for patients with detectable viral load (> 50 copies/mL) at the previous dosage.)
- New or recurrent stage 3 or 4 HIV/AIDS related events
- Deaths after one year
- (and 5 more...)
|
570 |
All |
18 Years and older (Adult, Older Adult) |
NCT00495326 |
ANRS 12146 CARINEMO |
CARINEMO |
December 2007 |
April 2011 |
April 2011 |
July 3, 2007 |
February 15, 2012 |
|
- Health centre of Alto Mae, Chamanculo district
Maputo, Mozambique - Health centre of Josue Macao
Maputo, Mozambique - Health centre of Malavane
Maputo, Mozambique
|
|
| 38 |
NCT01945268 |
Completed |
Influenza Vaccine To Prevent Adverse Vascular Events:Pilot |
|
- Drug: inactivated trivalent influenza vaccine
- Other: Sterile saline
|
Interventional
|
Phase 4 |
- McMaster University
- Population Health Research Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Feasibility
- Adverse cardiovascular event
- Cardiovascular death
|
107 |
All |
18 Years and older (Adult, Older Adult) |
NCT01945268 |
RCT IVVE Pilot |
IVVE:Pilot |
April 2015 |
December 2015 |
December 2015 |
September 18, 2013 |
August 4, 2017 |
|
- Maputo Central Hospital
Maputo, Mozambique - University of Philippines
Manila, Emita, Philippines - Mulago Hospital
Kampala, Uganda
|
|
| 39 |
NCT01697007 |
Completed |
A Phase II Trial to Assess the Safety and Immunogenicity of DNA Priming Administered by the ID Zetajet® With or Without ID Derma Vax™ Electroporation Followed by IM MVA Boosting in Healthy Volunteers in Tanzania and Mozambique |
- Vaccines
- HIV
- Safety
- Immunogenicity
|
- Biological: HIVIS DNA vaccine
- Device: Zetajet
- Device: Derma Vax Electroporation
- Biological: Modified Vaccinia Ankara (MVA-CDMR)
|
Interventional
|
Phase 2 |
- Muhimbili University of Health and Allied Sciences
- Swedish Institute for Infectious Disease Control
- Karolinska Institutet
- (and 7 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
|
- The presence of an interferon gamma ELISpot responses to a pool of HIV peptides encoded by the vaccine to which there was no response at baseline
- Grade 3 or above local and systemic solicited adverse events
- The presence of CD4+ and CD8+ T-cell cytokine responses to pools of HIV peptides assessed by Intracellular cytokine staining
|
198 |
All |
18 Years to 40 Years (Adult) |
NCT01697007 |
TaMoVac II |
TaMoVac II |
November 2012 |
December 2014 |
June 2015 |
October 2, 2012 |
June 29, 2015 |
|
- Instituto Nacional de Saude
Maputo, Mozambique - Muhimbili University of Health and Allied Sciences
Dar es Salaam, Tanzania - Mbeya Medical Research Programme
Mbeya, Tanzania
|
|
| 40 |
NCT01417988 |
Terminated |
Prevention of Early Mortality by Presumptive Tuberculosis (TB) Treatment |
- HIV Infection
- Tuberculosis
|
- Drug: Experimental: Empiric TB treatment
- Drug: ART only arm
|
Interventional
|
Phase 4 |
- Prof JMA Lange
- European and Developing Countries Clinical Trials Partnership (EDCTP)
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- All-cause mortality in the first 24 weeks after initiation of ART
- CD4 T cell absolute increase
- Causes of death
- (and 3 more...)
|
44 |
All |
18 Years and older (Adult, Older Adult) |
NCT01417988 |
AIGHD_001 |
PrOMPT |
August 2011 |
June 2013 |
June 2013 |
August 16, 2011 |
February 17, 2014 |
|
- Medical Research Unit, Albert Schweitzer Hospital
Lambaréné, Gabon - Ministry of Health -Provincial Heatlh Directorate of the Sofala Province (Direcção Provincial de Saúde de Sofala DPSS)
Beira, Mozambique - Infectious Diseases Institute University Makarere
Kampala, Uganda
|
|
| 41 |
NCT02023658 |
Completed |
Systems Analysis and Improvement to Optimize pMTCT |
|
- Other: pMTCT systems analysis and improvement
|
Interventional
|
Not Applicable |
- University of Washington
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- Network of AIDS Researchers of Eastern and Southern Africa
- (and 3 more...)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Uptake of HIV counseling and testing at first antenatal care visit
- Uptake of CD4 testing at antenatal care
- Use of appropriate ARVs in pregnancy for prophylaxis or initiation of ART during pregnancy
- Infant HIV determination
|
36 |
Female |
Child, Adult, Older Adult |
NCT02023658 |
44167-EG
R01HD075057 |
|
January 2014 |
March 2015 |
March 2015 |
December 30, 2013 |
January 26, 2017 |
|
- Ministry of Health
Bouake, Côte D'Ivoire - Ministry of Health
Nairobi, Kenya - Ministry of Health
Beira, Sofala, Mozambique
|
|
| 42 |
NCT02168569 |
Completed |
In Vivo Efficacy of Artemether-lumefantrine and Amodiaquine-artesunate in Mozambican Children |
|
- Drug: Coartem™ (Artemether-lumefantrine combination)
- Drug: Coarsucam™ (Amodiaquine-artesunate combination)
|
Interventional
|
Phase 4 |
- Centro de Investigacao em Saude de Manhica
- FHI 360
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To measure the Day 28, PCR corrected cure rates of artemether-lumefantrine (Coartem) and Amodiaquine-artesunate (Coarsucam).
- to evaluate the incidence of adverse events
- PCR uncorrected Day 28 efficacy of AL and AQ-AS
|
700 |
All |
6 Months to 59 Months (Child) |
NCT02168569 |
134/CNBS/11 |
MEFI |
June 2011 |
January 2012 |
January 2013 |
June 20, 2014 |
June 20, 2014 |
|
- Hospital Rural de Montepuez
Montepuez, Cabo Delgado, Mozambique - Hospital Rural de Chókwe,
Chokwe, Gaza, Mozambique - Centro de Investigação em Saúde de Manhiça
Manhiça, Maputo, Mozambique - (and 2 more...)
|
|
| 43 |
NCT03251196 |
Recruiting |
TB Sequel: Pathogenesis and Risk Factors of Long-term Sequelae of Pulmonary TB |
- Respiratory Tract Infections
- Tuberculosis, Pulmonary
|
- Other: No Intervention, and Observational Study
|
Observational
|
|
- The Aurum Institute NPC
- Ludwig-Maximilians - University of Munich
- Research Center Borstel
- (and 5 more...)
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Severe pulmonary function impairment
- Changes in impairment of pulmonary function
|
1600 |
All |
18 Years and older (Adult, Older Adult) |
NCT03251196 |
LMU-IMPH-TB Sequel-01 |
TBSEQUEL |
September 22, 2017 |
June 30, 2022 |
June 30, 2022 |
August 16, 2017 |
February 6, 2018 |
|
- The MRC-Unit
Fajara, Gambia - Instituto Nacional de Saúde
Maputo, Mozambique - The Clinical HIV Research Unit
Johannesburg, Gauteng, South Africa - NIMR-Mbeya Medical Research Centre
Mbeya, Tanzania
|
|
| 44 |
NCT01911494 |
Active, not recruiting |
Community Level Interventions for Pre-eclampsia |
- Pre-eclampsia
- Hypertension, Pregnancy Induced
|
- Behavioral: Community Engagement
- Device: PIERS on the Move mHealth decision aid
- Drug: Magnesium Sulfate
- Drug: Methyldopa
|
Interventional
|
Not Applicable |
- University of British Columbia
- Bill and Melinda Gates Foundation
- Olabisi Onabanjo University
- (and 3 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Maternal or Perinatal death or morbidity
- Birth preparedness and complication readiness
- Facility births
|
87500 |
Female |
15 Years to 49 Years (Child, Adult) |
NCT01911494 |
H12-03497
F12-01593 |
CLIP |
September 2013 |
May 2018 |
September 2018 |
July 30, 2013 |
May 4, 2018 |
|
- Jawaharlal Nehru Medical College, Karnataka Lingayat Education University
Belgaum, Karnataka, India - Centro de Investigacaoem Saude de Manhica (CISM)
Maputo, Mozambique - Centre for Research in Reproductive Health, Olabisi Onabanjo University
Sagamu, Ogun State, Nigeria - Aga Khan University
Karachi, Sindh, Pakistan
|
|
| 45 |
NCT02273765 |
Active, not recruiting |
Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis |
- HIV-1 Infection
- Tuberculosis
|
- Drug: Tenofovir + lamivudine + raltegravir
- Drug: Tenofovir + lamivudine + efavirenz
|
Interventional
|
Phase 3 |
- French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
- Merck Sharp & Dohme Corp.
- Ministry of Health, Brazil
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of patients in virologic success
- Time to death
- Frequency, type and time to new or recurrent AIDS-defining illnesses
- (and 10 more...)
|
460 |
All |
18 Years and older (Adult, Older Adult) |
NCT02273765 |
ANRS 12300 REFLATE TB2 |
REFLATE TB2 |
September 2015 |
September 2018 |
September 2019 |
October 24, 2014 |
August 6, 2018 |
|
- Laboratory of clinical research on STD/AIDS - IPEC/FIOCRUZ
Rio de Janeiro, Brazil - PACCI / CePReF Centre de Prise en charge de Recherche et de Formation
Abidjan, Côte D'Ivoire - Hôpital Saint Louis
Paris, France - (and 2 more...)
|
|
| 46 |
NCT02634450 |
Completed |
Early Infant Diagnosis Point of Care Pilot |
|
|
Interventional
|
Not Applicable |
- Instituto Nacional de Saúde, Mozambique
- Clinton Health Access Initiative, Mozambique
- UNICEF
- UNITAID
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- The proportion of HIV-positive infants initiating antiretroviral therapy within 60 days of sample collection
- the proportion of HIV-positive infants who initiated antiretroviral therapy that were retained in care at 90 days of follow-up.
- The median age at time of results received by patient
- (and 3 more...)
|
179 |
All |
up to 18 Months (Child) |
NCT02634450 |
POC EID PILOT |
|
September 2015 |
September 30, 2016 |
September 30, 2016 |
December 18, 2015 |
July 26, 2017 |
|
- Centro de Saude Moamba
Moamba, Maputo, Mozambique - Centro de Saude de Manga Loforte
Beira, Sofala, Mozambique - Centro de Saude de Ponta Gea
Beira, Sofala, Mozambique - (and 5 more...)
|
|
| 47 |
NCT01930084 |
Completed |
ENGAGE4HEALTH: A Combination Intervention Strategy for Linkage and Retention in Mozambique |
|
- Other: Point of care CD4+ after HIV diagnosis
- Other: Accelerated ART initiation
- Behavioral: SMS appointment reminders
- Other: Non-cash Financial Incentives
|
Interventional
|
Not Applicable |
- Columbia University
- United States Agency for International Development (USAID)
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Linkage to HIV care within 1 month of HIV testing and retention in care 12 months after testing.
- Time to linkage to care
|
2004 |
All |
18 Years and older (Adult, Older Adult) |
NCT01930084 |
AAAL1354
USAID-OAA-A-12-00027 |
E4H |
April 2013 |
July 2016 |
July 2016 |
August 28, 2013 |
February 8, 2017 |
|
- Chicuque Health Center
Inhambane, Mozambique - Massinga Health Center
Inhambane, Mozambique - Maxixe Health Center
Inhambane, Mozambique - (and 7 more...)
|
|
| 48 |
NCT00811421 |
Completed |
Evaluation of Alternative Antimalarial Drugs for Malaria in Pregnancy |
- Pregnancy
- Malaria
- HIV Infections
|
- Drug: Sulphadoxine-pyrimethamine
- Drug: Mefloquine (full dose)
- Drug: Mefloquine (split dose)
- (and 2 more...)
|
Interventional
|
Not Applicable |
- Hospital Clinic of Barcelona
- Barcelona Centre for International Health Research
- Institute of Tropical Medicine, University of Tuebingen
- (and 9 more...)
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Trial 1 (IPTp MQ vs IPTp SP): Low birth weight.
- Trial 2 (CTX+IPTp MQ vs. CTX+IPTp placebo): Peripheral parasitaemia.
- Trial 1: Prevalence of placental P. falciparum infection. Prevalence of moderate maternal anaemia at delivery.
- Trial 2: Prevalence of placental P. falciparum infection. Prevalence of low birth weight babies (< 2500 g).
|
5820 |
Female |
Child, Adult, Older Adult |
NCT00811421 |
IP.07.31080.002 |
MiPPAD |
September 2009 |
December 2012 |
December 2013 |
December 19, 2008 |
March 20, 2014 |
|
- Faculté des Sciences de la Santé (FSS), Université d'Abomey Calavi
Allada, Benin - Medical Rsearch Unit (MRU), Albert Schweitzer Hospital
Lambaréné, Gabon - Kenya Medical Research Institute (KEMRI)/ CDC
Kisumu, Kenya - (and 2 more...)
|
|
| 49 |
NCT00386763 |
Completed |
Efficacy and Safety of the Pediatric Formulation of Artemether- Lumefantrine in Children With Uncomplicated P. Falciparum Malaria. |
|
- Drug: Artemether-lumefantrine
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single
- Primary Purpose: Treatment
|
- Proportion of patients free of parasites at day 28.
- Proportion of patients free of parasites at 7 days and at 14 days
- Time to clearance from parasites
- (and 3 more...)
|
890 |
All |
up to 12 Years (Child) |
NCT00386763 |
CCOA566B2303 |
|
August 2006 |
|
March 2007 |
October 12, 2006 |
March 12, 2009 |
|
- Novartis
Benin, Benin - Novartis
Kenya, Kenya - Novartis
Mali, Mali - (and 2 more...)
|
|
| 50 |
NCT00203801 |
Completed |
Combination Antimalarials in Uncomplicated Malaria |
|
- Drug: Sulfadoxine-pyrimethamine
- Drug: Artesunate plus sulfadoxine-pyrimethamine
- Drug: Artemether-lumefantrine
|
Interventional
|
Not Applicable |
- University of Cape Town
- World Health Organization
- Medical Research Council, South Africa
- Global Fund
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Therapeutic efficacy defined as:
- Adequate Clinical and Parasitological Response (ACPR), Early Treatment Failure (ETF), Late Treatment Failure (LTF), defined as Late Clinical Failure (LCF) and Late Parasitological Failure (LPF);
- Sensitive or parasitological failure (RI, early and late, RII, RIII)
- (and 8 more...)
|
700 |
All |
12 Months and older (Child, Adult, Older Adult) |
NCT00203801 |
SEACAT 01 Mono (Am 1,2,3,5,6) |
|
January 2002 |
|
July 2005 |
September 20, 2005 |
September 11, 2006 |
|
- Bela Vista Clinic
Bela Vista, Matutuine, Mozambique - Namaacha Clinic
Namaacha, Mozambique - Ndumo Clinic
Ndumo, KwaZulu Natal, South Africa - (and 4 more...)
|
|
| 51 |
NCT03600844 |
Recruiting |
Evaluating the Effects of Community Delivery of Malaria Intermittent Preventive Treatment on Pregnant Women and Babies |
|
- Behavioral: Community distribution of SP for IPTp
|
Interventional
|
Not Applicable |
- Jhpiego
- Barcelona Institute for Global Health
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- IPTp3 Coverage
- IPTp1 Coverage
- ANC 4 coverage
- (and 3 more...)
|
10602 |
Female |
15 Years to 49 Years (Child, Adult) |
NCT03600844 |
TIPTOP_HHS_2018
2017-13-TIPTOP |
TIPTOP |
April 2, 2018 |
October 2021 |
October 2021 |
July 26, 2018 |
July 26, 2018 |
|
- Kenge District, Community Setting
Kenge, Kwango, Congo, The Democratic Republic of the - Bulungu District, Community Setting
Bulungu, Kwilu, Congo, The Democratic Republic of the - Mananjary District, Community Setting
Mananjary, Fianarantsoa, Madagascar - (and 5 more...)
|
|
| 52 |
NCT03284710 |
Recruiting |
Safety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine |
|
- Biological: ALVAC-HIV (vCP2438)
- Biological: Bivalent Subtype C gp120/MF59
- Biological: Bivalent Subtype C gp120 admixed with Al(OH)3 Suspension
- Biological: Bivalent Subtype C gp120
|
Interventional
|
Phase 1
Phase 2 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- HIV Vaccine Trials Network
- Sanofi Pasteur, a Sanofi Company
- GlaxoSmithKline
|
NIH / Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Prevention
|
- Occurrence and level of vaccine-induced systemic IgG Ab binding to the 3 gp120 Env proteins contained in the vaccine regimen (ZM96, TV1.C, and 1086.C)
- Occurrence and level of vaccine-induced serum IgA Ab binding to the 3 gp120 Env proteins contained in the vaccine regimen (ZM96, TV1.C, and 1086.C)
- Frequency of severe local and systemic reactogenicity signs and symptoms (pain, tenderness, erythema, induration, fever, malaise/fatigue, myalgia, headache, nausea, vomiting, chills, arthralgia)
- (and 5 more...)
|
132 |
All |
18 Years to 40 Years (Adult) |
NCT03284710 |
HVTN 107 |
HVTN107 |
June 19, 2017 |
September 30, 2019 |
September 30, 2019 |
September 15, 2017 |
September 15, 2017 |
|
- Polana Canico Health Research and Training Center (CISPOC), National Institute of Health (INS) CRS
Maputo, Mozambique - Aurum Tembisa CRS
Johannesburg, Gauteng, South Africa - Soweto HVTN CRS
Johannesburg, Gauteng, South Africa - (and 3 more...)
|
|
| 53 |
NCT02128139 |
Unknown † |
Infective Endocarditis in Developing Countries, a Prospective, Observational, Multicentre Study |
|
|
Observational
|
|
- Institut National de la Santé Et de la Recherche Médicale, France
- Ministry of Health, Mozambique
- War Memorial Hospital
- (and 2 more...)
|
Other / U.S. Fed |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Mortality at 1 month follow-up
- Mortality at 6 months follow-up
|
500 |
All |
1 Year and older (Child, Adult, Older Adult) |
NCT02128139 |
EndoDev
Cardiology and Development |
EndoDev |
June 2014 |
June 2015 |
June 2015 |
May 1, 2014 |
May 1, 2014 |
|
- Joseph Kado
Suva, Fiji - Paul N. Newton
Vientiane, Lao People's Democratic Republic - Beatriz Ferreira
Maputo, Mozambique - (and 3 more...)
|
|
| 54 |
NCT00670761 |
Completed |
Misoprostol for the Treatment of Incomplete Abortion |
|
- Drug: misoprostol
- Procedure: MVA
|
Interventional
|
Not Applicable |
- Gynuity Health Projects
- Befelatanana Maternity Centre
- Municipal Clinical Hospital No. 1
- (and 7 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- complete resolution of signs/symptoms of incomplete abortion without recourse to surgery at any point for any reason
|
720 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00670761 |
2.2.1 |
|
July 2004 |
April 2010 |
December 2010 |
May 2, 2008 |
July 27, 2016 |
|
- Hôpital de District Sanitaire Dandé
Bobo Dioulasso, Burkina Faso - Hôpital de District Sanitaire de Ziniaré
Ouagadougou, Burkina Faso - Befelatanana Maternity Centre
Antananarivo, Madagascar - (and 3 more...)
|
|
| 55 |
NCT03060629 |
Recruiting |
A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa |
|
- Biological: Ad26.Mos4.HIV
- Biological: Clade C gp140
- Biological: Placebo
|
Interventional
|
Phase 2 |
- Janssen Vaccines & Prevention B.V.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Vaccine Efficacy (VE) as Derived From Confirmed HIV-1 Infections Diagnosed Between the Month 7 and Month 24 Visits
- Percentage of Participants Experiencing Reactogenicity Sign or Symptom
- Percentage of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability
- (and 9 more...)
|
2600 |
Female |
18 Years to 35 Years (Adult) |
NCT03060629 |
CR108263
VAC89220HPX2008
HVTN 705
HVTN 705/VAC89220HPX2008 |
|
November 3, 2017 |
November 2, 2020 |
February 1, 2022 |
February 23, 2017 |
September 12, 2018 |
|
- UNC Lilongwe Project
Lilongwe, Malawi - Polana Caniço Health Research and Training Center (CISPOC)
Maputo, Mozambique - Josha Research
Bloemfontein, South Africa - (and 22 more...)
|
|
| 56 |
NCT01734434 |
Completed |
Study to Identify Factors Influencing Access of Pregnant Women and Their Infants to Local Healthcare Systems |
- Pregnancy, Newborn Health
|
|
Observational
|
|
- Novartis Vaccines
- Novartis
|
Industry |
- Observational Model: Ecologic or Community
- Time Perspective: Prospective
|
- Identify factors that might influence if a pregnant woman
|
3257 |
Female |
Child, Adult, Older Adult |
NCT01734434 |
V98_15OB |
|
November 2012 |
January 2015 |
January 2015 |
November 27, 2012 |
February 25, 2015 |
|
- Centro Sanitario de Santo Domingo
Santo Domingo, Dominican Republic - Maternidad Nuestra Senora de La Altagracia
Santo Domingo, Dominican Republic - CISM Manhica Health Research Centre
Manhiça, Mozambique - (and 7 more...)
|
|
| 57 |
NCT02598388 |
Active, not recruiting |
Safety, Tolerability and Immunogenicity Study of 2 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo |
|
- Biological: Ad26.ZEBOV
- Biological: MVA-BN-Filo
- Biological: Placebo
|
Interventional
|
Phase 2 |
- Janssen Vaccines & Prevention B.V.
- Walter Reed Army Institute of Research (WRAIR)
|
Industry / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Number of Participants With Adverse Events
- Number of Participants With Serious Adverse Events
- Number of Participants with Solicited Local and Systemic Adverse Events
- (and 2 more...)
|
578 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT02598388 |
CR108062
VAC52150EBL2003 |
|
December 10, 2015 |
December 25, 2018 |
December 28, 2018 |
November 5, 2015 |
October 10, 2018 |
|
- Silver Spring, Maryland, United States
- Kericho, Kenya
- Kisumu, Kenya
- (and 4 more...)
|
|
| 58 |
NCT03167242 |
Recruiting |
Efficacy and Safety of KAF156 in Combination With LUM-SDF in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria |
- Acute Uncomplicated Plasmodium Falciparum Malaria
|
- Drug: KAF156 and LUM-SDF
- Drug: Coartem
|
Interventional
|
Phase 2 |
- Novartis Pharmaceuticals
- Medicines for Malaria Venture
- Novartis
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- PCR-corrected adequate clinical and parasitological response (ACPR)
- Adverse events (AE) incidence and severity, liver and kidney function tests and electrocardiogram (ECG) abnormalities
- PCR-uncorrected ACPR
- (and 8 more...)
|
512 |
All |
2 Years and older (Child, Adult, Older Adult) |
NCT03167242 |
CKAF156A2202 |
|
August 2, 2017 |
September 26, 2019 |
October 11, 2019 |
May 25, 2017 |
August 14, 2018 |
|
- Novartis Investigative Site
Lambarene, Gabon - Novartis Investigative Site
Banjul, Gambia - Novartis Investigative Site
Siaya, Kenya - (and 7 more...)
|
|
| 59 |
NCT02568215 |
Active, not recruiting |
Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection in Women |
|
- Biological: VRC01
- Biological: Placebo for VRC01
|
Interventional
|
Phase 2 |
- National Institute of Allergy and Infectious Diseases (NIAID)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Number of participants with local and systemic reactogenicity signs and symptoms
- Number of participants with adverse events (AEs)
- Number of participants with severe adverse events (SAEs)
- (and 6 more...)
|
1900 |
Female |
18 Years to 50 Years (Adult) |
NCT02568215 |
HVTN 703/HPTN 081
12045 |
|
May 2016 |
December 2021 |
|
October 5, 2015 |
October 16, 2018 |
|
- Gaborone CRS
Gaborone, South-East District, Botswana - Kisumu Crs
Kisumu, Nyanza, Kenya - Blantyre CRS
Blantyre, Southern Region, Malawi - (and 18 more...)
|
|
| 60 |
NCT03231449 |
Active, not recruiting |
A Survey of Hospitalizations in Cardiology Units in Sub-Saharan Africa |
- Acute Coronary Syndrome
- Heart Failure
- Syncope
- (and 8 more...)
|
- Other: observation of current care
|
Observational
|
|
- Cardiologie et Développement
- Institut National de la Santé Et de la Recherche Médicale, France
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Description of patients in cardiology unit in sub-Saharan Africa:socio-demographic characterization
- Description of patients in cardiology unit in sub-Saharan Africa:causes of hospitalization
- Description of patients in cardiology unit in sub-Saharan Africa: co-morbidities
- (and 6 more...)
|
5000 |
All |
Child, Adult, Older Adult |
NCT03231449 |
001 |
FEVRIER |
February 1, 2017 |
December 2020 |
February 2021 |
July 27, 2017 |
May 25, 2018 |
|
- Centre national hospitalier et universitaire Koutoukou Maga
Cotonou, Benin - Centre médical Paul IV
Ouagadougou, Burkina Faso - Hopital militaire de Kamenge et polyclinique maison médicale
Bujumbura, Burundi - (and 17 more...)
|
|
| 61 |
NCT02762851 |
Recruiting |
Influenza Vaccine To Prevent Adverse Vascular Events (RCT-IVVE) |
|
- Other: Sterile saline
- Drug: inactivated trivalent influenza vaccine
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Adverse cardiovascular event
- Cardiovascular (CV) death
|
5000 |
All |
18 Years and older (Adult, Older Adult) |
NCT02762851 |
RCT-IVVE 2015 |
RCT-IVVE |
June 2016 |
December 2019 |
December 2020 |
May 5, 2016 |
April 18, 2018 |
|
- Douala General Hospital
Douala, Cameroon - Fuwai Hospital
Beijing, Xicheng District, China - Centre for Chronic Disease Control
New Delhi, India - (and 10 more...)
|
|
| 62 |
NCT01992900 |
Completed |
A Pharmacokinetic/Pharmacodynamic Study of Eurartesim Dispersible Formulation in Infants With P.Falciparum Malaria |
|
- Drug: Eurartesim dispersible oral tablet
- Drug: eurartesim film coated tablet
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Comparison of peak plasma concentration of Dihydroartemisinin in the two studied formulations
- Comparison of area under the plasma concentration versus time curve of Dihydroartemisinin in the two studied formulations.
- Comparison of peak plasma concentration of Piperaquine in the two studied formulations
- (and 7 more...)
|
300 |
All |
6 Months to 12 Months (Child) |
NCT01992900 |
ST3073-ST3074-DM-12-002
2013-002255-15 |
|
November 2013 |
July 2015 |
January 2016 |
November 25, 2013 |
November 8, 2016 |
|
- Centre Muraz
Bobo Dioulasso, Burkina Faso - Centre National de Recherche et de Formation en Paludisme
Ouagadougou, Burkina Faso - Kinshasa School of Public Health, School of Medicine, University of Kinshasa
Kinshasa, Congo, The Democratic Republic of the - (and 4 more...)
|
|
| 63 |
NCT01198366 |
Completed
Has Results |
Study of AERAS-402 in Healthy Infants |
|
- Biological: AERAS-402 1.5 x 10^10 vp
- Biological: AERAS-402 3.0 x 10^10 vp
- Biological: AERAS-402 1.0 x 10^11 vp
- Biological: Placebo
|
Interventional
|
Phase 1
Phase 2 |
- Aeras
- European and Developing Countries Clinical Trials Partnership (EDCTP)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Adverse Events Collected Per Subject
- Percentage of Cells Expressing Various Cytokines Will be Measured by Intracellular Cytokine Staining (ICS) in All Subjects
- Interferon-gamma (IFN-gamma) Enzyme-linked Immunospot (ELISpot) Response: Spot Forming Units/10^6 PBMC According to ELISpot Assay
- (and 2 more...)
|
487 |
All |
112 Days to 182 Days (Child) |
NCT01198366 |
C-029-402 |
|
September 2010 |
January 2014 |
April 2014 |
September 10, 2010 |
May 8, 2017 |
August 4, 2015 |
- Boro Heath Center
Boro, Kenya - KEMRI/CDC Research and Public Heath Collaboration
Kisumu, Kenya - Siaya District Hospital
Siaya, Kenya - (and 4 more...)
|
|
| 64 |
NCT02661464 |
Recruiting |
Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo |
|
- Biological: Ad26.ZEBOV
- Biological: MVA-BN-Filo
|
Interventional
|
Phase 3 |
- Janssen Vaccines & Prevention B.V.
- Bavarian Nordic GmbH
|
Industry / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Percentage of Serious Adverse Events (SAEs)
- Percentage of pregnancies with estimated conception within 28 days after vaccination with MVA-BN-Filo or within 3 months after vaccination with Ad26.ZEBOV
- Percentage of pregnancies (with estimated conception within 28 days after vaccination with MVA-BN-Filo or within 3 months after vaccination with Ad26.ZEBOV) by pregnancy outcome
- (and 2 more...)
|
922 |
All |
up to 71 Years (Child, Adult, Older Adult) |
NCT02661464 |
CR108112
2015-004139-11
VAC52150EBL4001 |
|
May 31, 2016 |
May 1, 2022 |
April 11, 2023 |
January 22, 2016 |
October 10, 2018 |
|
- Optimal Research, LLC
Rockville, Maryland, United States - Optimal Research, LLC
Rockville, Maryland, United States - Walter Reed Army Institute of Research
Silver Spring, Maryland, United States - (and 25 more...)
|
|
| 65 |
NCT00393679 |
Completed |
Evaluation of 4 Artemisinin-based Combinations for Treating Uncomplicated Malaria in African Children |
|
- Drug: amodiaquine-artesunate (ASAQ)
- Drug: dihydroartemisinin-piperaquine (DHAPQ)
- Drug: artemether-lumefantrine (AL)
- Drug: Lapdap (Chlorproguanil-Dapsone) + artesunate (AS)
|
Interventional
|
Phase 3 |
- Institute of Tropical Medicine, Belgium
- Liverpool School of Tropical Medicine
- East African Network for Monitoring Antimalarial Treatment
- (and 10 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- PCR unadjusted treatment failure (TF28U): all treatment failures detected during the active follow up, regardless of genotyping.
- PCR adjusted treatment failure up to day 28 (TF28A): all early failures before day 14 plus the recurrent parasitaemias detected at day 14 or later and classified by genotyping as recrudescence.
- PCR unadjusted treatment failure up to day 63 (TF63U): TF28U plus all cases of recurrent parasitaemia (symptomatic or asymptomatic) detected between day 29 and day 63 by passive follow up, regardless of genotyping
- (and 10 more...)
|
4112 |
All |
6 Months to 59 Months (Child) |
NCT00393679 |
4 ABC
IRB Antwerp: 6/40/187 |
|
July 2007 |
December 2009 |
December 2009 |
October 30, 2006 |
February 3, 2014 |
|
- Centre Muraz/IRSS
Bobo-Dioulasso, Burkina Faso - Albert Schweitzer Hospital
Lambaréné, Gabon - Manhiça Health Research Center
Manhica, Mozambique - (and 5 more...)
|
|
| 66 |
NCT02497612 |
Recruiting |
To Evaluate the Efficacy of a Single Dose Regimen of Ferroquine and Artefenomel in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria |
- Plasmodium Falciparum Infection
|
- Drug: Ferroquine SSR97193
- Drug: Artefenomel
- Other: Placebo
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percentage of patients with Polymerase Reaction Chain (PCR)-adjusted Adequate Clinical and Parasitological Response (ACPR)
- Percentage of patients with PCR - adjusted ACPR
- Percentage of patients with PCR - crude ACPR
- (and 7 more...)
|
662 |
All |
6 Months to 69 Years (Child, Adult, Older Adult) |
NCT02497612 |
DRI12805
U1111-1155-7960 |
FALCI |
July 25, 2015 |
April 2, 2021 |
April 2, 2021 |
July 14, 2015 |
October 9, 2018 |
|
- Investigational Site Number 204001
Cotonou, Benin - Investigational Site Number 854001
Nanoro, Burkina Faso - Investigational Site Number 854003
Niangoloko, Burkina Faso - (and 11 more...)
|
|
| 67 |
NCT02199951 |
Unknown † |
Introduction of Eurartesim® in Burkina Faso, Mozambique, Ghana and Tanzania |
|
- Drug: Dihydroartemisinin and piperaquine
|
Observational
|
|
- INDEPTH Network
- Ministry of Health, Ghana
- Ifakara Health Research and Development Centre
- (and 2 more...)
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Adverse events
- Adverse events of special interest
|
10000 |
All |
6 Months and older (Child, Adult, Older Adult) |
NCT02199951 |
INESS 02/2012
GRANT ID#. 48363.01 |
|
September 2013 |
August 2014 |
December 2014 |
July 25, 2014 |
July 25, 2014 |
|
- Nouna Research Centre
Nouna, Burkina Faso - Nanoro Health Research Centre
Ouagadougou, Burkina Faso - INDEPTH Network
Accra, Ghana - (and 4 more...)
|
|
| 68 |
NCT02083380 |
Completed
Has Results |
Phase II Efficacy Study of Artefenomel & Piperaquine in Adults & Children With P. Falciparum Malaria. |
- Uncomplicated Plasmodium Falciparum Malaria
|
- Drug: Artefenomel 800mg: piperaquine 640mg
- Drug: Artefenomel 800mg: piperaquine 960mg
- Drug: Artefenomel 800mg: piperaquine 1440mg
|
Interventional
|
Phase 2
Phase 3 |
- Medicines for Malaria Venture
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- PCR-adjusted ACPR at Day 28 in the PP Population (All Patients)
- PCR-adjusted ACPR at Day 28 in the PP Population: Asia (All Ages)
- PCR-adjusted ACPR at Day 28 in the PP Population: Africa (All Ages)
- (and 21 more...)
|
448 |
All |
6 Months to 70 Years (Child, Adult, Older Adult) |
NCT02083380 |
MMV_OZ439_13_003 |
|
July 2014 |
October 2015 |
November 2015 |
March 11, 2014 |
March 10, 2017 |
January 30, 2017 |
- Centre D'Étude Et de Recherchesur Le Paludisme Associé À La Grossesse Et À L'Enfance (Cerpage) Cerpage
Cotonou, Benin - Centre National de Recherche et de Formation sur le paludisme (CNRFP) Ouagadougou, Kadiogo
Ouagadougou, Burkina Faso - Clinical research Unit of Nanoro (CRUN)/CMA Saint Camille de Nanoro, 11 BP 218 Ouagadougou CMS 11
Ouagadougou, Burkina Faso - (and 6 more...)
|
|
| 69 |
NCT00866619 |
Completed |
Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa |
|
- Biological: Malaria Vaccine 257049
- Biological: Meningococcal C Conjugate Vaccine
- Biological: Cell-culture rabies vaccine
- (and 2 more...)
|
Interventional
|
Phase 3 |
- GlaxoSmithKline
- The PATH Malaria Vaccine Initiative (MVI)
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- For a primary schedule, the occurrence of cases of malaria meeting the primary case definition for clinical malaria disease.
- Efficacy against severe malaria disease: for a primary schedule (pooled with and without a boost), the occurrence of severe malaria disease meeting the primary and secondary case definitions.
- Efficacy against severe malaria disease: for a primary schedule with and without a boost, the occurrence of severe malaria disease meeting the primary and secondary case definitions.
- (and 46 more...)
|
15459 |
All |
6 Weeks to 17 Months (Child) |
NCT00866619 |
110021 |
|
March 27, 2009 |
March 1, 2011 |
January 31, 2014 |
March 20, 2009 |
April 25, 2017 |
|
- GSK Investigational Site
Ouagadougou, Burkina Faso - GSK Investigational Site
Lambaréné, Gabon - GSK Investigational Site
Kintampo, Ghana - (and 7 more...)
|
|
| 70 |
NCT00216333 |
Unknown † |
Multicenter Trial for the Evaluation of a Fixed Dose Combined Tablet for the Treatment of Pulmonary Tuberculosis |
|
- Drug: combined fixed dose combination
|
Interventional
|
Phase 4 |
- International Union Against Tuberculosis and Lung Diseases
- United States Agency for International Development (USAID)
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Efficacy : combined rate of failure at the end of treatment and relapse by 30 months.
- Safety : occurrence of serious adverse events at any time during chemotherapy
- Sputum culture results at two months of chemotherapy
- Rate of completion of chemotherapy according to the protocol
|
1500 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00216333 |
IUATLD CT Study C |
|
December 2003 |
|
June 2007 |
September 22, 2005 |
September 13, 2006 |
|
- Service de Pneumo-phtisiologie de Matiben
Algiers, Algeria - Program Nal. de Control de la Tuberculosis
Santa Cruz, Bolivia - Centro Internacional de Entrenamiento
Cali, Colombia - (and 6 more...)
|
|
| 71 |
NCT00541385 |
Completed |
Pyronaridine Artesunate 3:1 Granule Formulation vs. Coartem© Crushed Tablets in P. Falciparum Malaria Pediatric Patients |
|
- Drug: pyronaridine artesunate
- Drug: arthemeter lumefantrine
|
Interventional
|
Phase 3 |
- Medicines for Malaria Venture
- Shin Poong Pharmaceuticals
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- PCR corrected ACPR on Day 28
- PCR-corrected ACPR on Day 14
- Incidence and severity of adverse events and of cllinically significant laboratory results, ECG, vital signs or physical examination abnormalities
|
534 |
All |
up to 12 Years (Child) |
NCT00541385 |
SP-C-007-07 |
|
October 2007 |
September 2008 |
November 2008 |
October 10, 2007 |
January 22, 2009 |
|
- Centre National de Recherche et de Formation sur le Paludisme
Ouagadougou, Burkina Faso - Ecole de Santé Publique, Faculté de Médecine, Université de Kinshasa
Kinshasa, DRC, Congo - Unité de Paludologie de l'Institut Pasteur d'Abidjan
Abdijan, Côte D'Ivoire - (and 5 more...)
|
|
| 72 |
NCT00422084 |
Completed |
Pyronaridine Artesunate (3:1) Versus Coartem® in P Falciparum Malaria Patients |
|
- Drug: Pyronaridine artesunate
- Drug: Coartem® (artemether lumefantrine)
|
Interventional
|
Phase 3 |
- Medicines for Malaria Venture
- Shin Poong Pharmaceuticals
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- PCR-corrected adequate clinical and parasitological response (ACPR) rate on Day 28
- Treatment success or failures will be classified according to WHO Guidelines 2005
- Incidence and severity of adverse events and of clinically significant laboratory results, ECG, vital signs or physical examination abnormalities
- (and 6 more...)
|
1269 |
All |
3 Years to 60 Years (Child, Adult) |
NCT00422084 |
SP-C-005-06 |
|
January 2007 |
April 2008 |
May 2008 |
January 15, 2007 |
May 20, 2008 |
|
- Ecole de Santé Publique, Faculté de Médecine, Université de Kinshasa
Kinshasa, DRC, Congo - Farafenni Field Station, c/o: MRC Laboratories
Fajara, Gambia - Komfo Anoykye Teaching Hospital
Kumasi, Ghana - (and 7 more...)
|
|
Create an RSS feed from your search for:
Download the search results for: